Mectizan (Ivermectin)

Ivermectin activates glutamate‑gated chloride channels found in the nerve and muscle cells of invertebrates. This causes an influx of chloride ions, leading to hyperpolarization, paralysis, and ultimately death of the parasite, while human cells are largely unaffected because they lack these specific channels.

The appropriate dose of Mectizan is determined by a qualified prescriber based on the specific indication, patient weight, and clinical guidelines. Dosing regimens can vary, so it is essential to follow the healthcare professional’s instructions.

Mectizan is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Caution is advised during breastfeeding, and infants should be monitored for adverse effects.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with other antiparasitics such as albendazole or diethylcarbamazine, ivermectin has a unique mechanism targeting glutamate‑gated chloride channels, offering high efficacy against a broad range of parasites. Its safety profile is well‑established, though choice of therapy depends on the specific infection, regional resistance patterns and patient factors.

Mectizan tablets should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s potency and stability throughout its shelf life.

Mectizan is administered orally as a tablet. The tablet is swallowed whole with water, typically on an empty stomach unless otherwise directed by the prescriber. The exact timing and frequency depend on the condition being treated.

Serious risks, though rare, include severe hypotension, hepatic dysfunction, and neurological events such as seizures or encephalopathy. Patients with high Loa loa microfilarial loads are at increased risk for serious adverse reactions and should be evaluated carefully before treatment.

Mectizan is contraindicated in individuals with known hypersensitivity to ivermectin or any component of the tablet. Caution is also advised for patients with severe hepatic impairment, uncontrolled infections with Loa loa, and those taking strong CYP3A4 or P‑glycoprotein inhibitors without medical supervision.